Skip to main content
Clinical Trials/EUCTR2007-003478-25-IT
EUCTR2007-003478-25-IT
Active, not recruiting
Not Applicable

?The effect of acute and chronic administration of the CCK1 receptor antagonist Dexloxiglumide (CR2017) on 24-h pH metry, LES motor and symptoms? pattern, in patients with gastroesophageal reflux disease (GERD). A randomized, double-blind, placebo controlled study? - ND

ROTTAPHARM / ROTTA RESEARCH LABORATORIUM0 sitesMarch 6, 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
gastroesaphageal reflux disease (GERD)
Sponsor
ROTTAPHARM / ROTTA RESEARCH LABORATORIUM
Status
Active, not recruiting
Last Updated
14 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 6, 2009
End Date
TBD
Last Updated
14 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
ROTTAPHARM / ROTTA RESEARCH LABORATORIUM

Eligibility Criteria

Inclusion Criteria

  • \- males or female \- age \>\=18 and \<\=70 \- patients with the symptoms of gastroesaphageal reflux disease (GERD) \- heartburn, gastric burning sensation and regurgitation \- according to the following: presence of all the 3 symptoms, regardless of intensity or duration, presence of at least one of the 3 symptoms, with intensity at least moderate or duration at least between 15 and 30 minutes daily \- signed informed consent \- use of contraceptive methods for women of child\-bearing potential
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range

Exclusion Criteria

  • \- hiatal hernia \- abdominal surgery \- pregnant or breast\-feeding females \- significant diseases \- use of prohibited medication (among which, H2 blockers and antiacids)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-GBInstitut de Recherches Internationales Servier36
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-DEInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1
EUCTR2011-000579-15-FIInstitut de Recherches Internationales Servier
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1
EUCTR2011-000579-15-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER36
Active, not recruiting
Not Applicable
Effects of acute and chronic oral administration of S44121 versus placebo on cardiac arrhythmia during exercise testing in patients with catecholaminergic polymorphic ventricular tachycardia type 1Catecholaminergic polymorphic ventricular tachycardia type 1MedDRA version: 14.1Level: LLTClassification code 10036095Term: Polymorphic ventricular tachycardiaSystem Organ Class: 100000004849Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2011-000579-15-HUInstitut de Recherches Internationales Servier36